查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
藥物研發中人工智慧 (AI) 的全球市場：按產品、按治療領域、按流程、按使用案例、按技術、按最終用戶、按地區 - 預測到 2028 年
市場調查報告書
商品編碼
1384291

藥物研發中人工智慧 (AI) 的全球市場：按產品、按治療領域、按流程、按使用案例、按技術、按最終用戶、按地區 - 預測到 2028 年

Artificial Intelligence / AI in Drug Discovery Market by Offering, Process, Drug Design, Dry Lab, Wet Lab & Region - Global Forecast to 2028
出版日期: | 出版商: MarketsandMarkets | 英文 369 Pages | 訂單完成後即時交付

價格
簡介目錄
調查範圍
調查年份 2021-2028
基準年 2022年
預測期 2023-2028
考慮單位 金額（十億美元）
部分 按產品、按治療領域、按流程、使用案例、按技術、按最終用戶、按地區
目標區域 北美、歐洲、亞太地區、南美洲、中東/非洲

藥物研發領域的全球人工智慧 (AI) 市場預計將從 2023 年的 9 億美元增加到 2028 年的 49 億美元，預測期內年複合成長率為 40.2%。

人工智慧透過分析複雜的生物資料加速潛在藥物研發標靶的識別和檢驗。這加速了治療性介入的生物學相關目標的選擇。機器學習等人工智慧技術可以實現快速分析和決策，減少藥物研發過程所需的時間和資源。這種效率可以讓您在快節奏的製藥業中獲得競爭優勢。因此，上述因素將推動該市場的成長。另一方面，技術純熟勞工的短缺是預測期內一定程度上限制市場成長的關鍵因素。

透過提供，軟體和服務將在 2022 年佔據市場最大的市場佔有率，並且預計在預測期內將以最快的年複合成長率成長。透過我們的服務獲得人工智慧技術和專業知識可以降低製藥公司在藥物研發中實施人工智慧的障礙。這對於不具備廣泛的內部人工智慧能力的中小型企業尤其有利，使他們能夠利用人工智慧的力量，而無需進行大量的前期投資。

從技術角度來看，機器學習領域在 2022 年將在全球市場中佔據最大佔有率，預計在預測期內將以最高年複合成長率成長。機器學習可以創建預測模型來預測潛在候選藥物在人體內的行為。這有助於識別成功機率最高的化合物，從而減少與不成功候選化合物相關的成本和時間。機器學習透過分析患者資料來預測個體對藥物的反應，有助於制定個體化治療策略。這使得根據遺傳、分子和臨床資訊製化治療方法變得更加容易，從而產生更有效的結果，並有助於加速藥物研發過程，這是支持該細分市場市場成長的因素。它已成為其中的一部分。

按使用案例，小分子設計和最佳化領域在 2022 年藥物研發人工智慧市場中佔據最大佔有率。將人工智慧應用於小分子化合物的設計和最佳化有兩個主要目的。首先，它透過篩選現有化學庫或透過產生從頭設計來幫助識別命中和先導化合物。其次，人工智慧可以最佳化已識別的命中化合物，以確保結合親和性、毒性和合成等有利特性，最終開發出更有效、更安全的候選藥物。這些因素有助於開發和完善針對藥物研發使用案例客製化的人工智慧演算法。

到 2022 年，北美將成為藥物研發人工智慧最大、成長最快的區域市場。北美擁有眾多製藥巨頭和生物技術創新者，他們正在積極探索人工智慧在藥物研發方面的能力。這些產業巨頭正大力投資人工智慧驅動的研發，推動市場成長。北美擁有成熟的製藥和醫療保健法律規範，可以促進人工智慧技術的整合，同時確保符合行業標準和指南。上述因素將推動北美藥物研發人工智慧市場的發展。

該報告研究了藥物研發發現市場中的全球人工智慧 (AI)，並透過產品、治療領域、流程、使用案例、技術、最終用戶、地區和進入市場的公司等分析了趨勢。資料集等。

目錄

第1章 簡介

第2章 調查方法

第3章 執行摘要

第4章 重要考察

第5章 市場概況

  • 介紹
  • 市場動態

第6章 業界考察

  • 主要產業趨勢概述
  • 供應鏈分析
  • 波特五力分析
  • 生態系/市場地圖
  • 技術分析
  • 價格分析
  • 商業模式
  • 案例研究分析
  • 法規分析
  • 專利分析
  • 重大會議和活動（2023年第一季- 2024年季度）
  • 影響客戶業務的趨勢/干擾
  • 主要相關人員和採購標準
  • 人工智慧衍生的臨床資產
  • 未滿足的需求

第7章 （按產品分類）

  • 介紹
  • 服務
  • 軟體

第8章 （按技術）

  • 介紹
  • 機器學習
  • 自然語言處理
  • 上下文感知處理和計算
  • 其他

第9章 （按治療領域）

  • 介紹
  • 腫瘤學
  • 感染疾病
  • 神經科
  • 心血管疾病
  • 免疫學
  • 代謝性疾病
  • 其他

第10章 （按流程）

  • 介紹
  • 目標識別和選擇
  • 目標檢驗
  • 命中識別和優先排序
  • 潛在客戶識別/從點擊中產生潛在客戶
  • 潛在客戶最佳化
  • 候選人的選擇和檢驗

第11章（使用案例）

  • 介紹
  • 小分子設計與最佳化
  • 了解疾病
  • 安全性和毒性
  • 疫苗設計和最佳化
  • 抗體及其他生物設計與最佳化

第12章（按最終用戶）

  • 介紹
  • 製藥和生物技術公司
  • CRO
  • 研究中心以及學術和政府機構

第13章（按地區）

  • 介紹
  • 北美洲
  • 歐洲
  • 亞太地區
  • 南美洲
  • 中東/非洲

第14章競爭形勢

  • 主要參與企業的策略
  • 收益分析
  • 市場佔有率分析
  • 企業評價矩陣
  • 新興企業/小型企業評估矩陣
  • 競爭格局及趨勢

第15章公司簡介

  • 主要參與企業
    • NVIDIA CORPORATION
    • EXSCIENTIA
    • GOOGLE
    • BENEVOLENTAI
    • RECURSION
    • INSILICO MEDICINE
    • SCHRODINGER, INC.
    • MICROSOFT CORPORATION
    • ATOMWISE INC.
    • ILLUMINA, INC.
    • NUMEDII, INC.
    • XTALPI INC.
    • IKTOS
    • TEMPUS LABS
    • DEEP GENOMICS, INC.
    • VERGE GENOMICS
    • BENCHSCI
    • INSITRO
    • VALO HEALTH
    • BPGBIO, INC.
  • 其他新興企業
    • PREDICTIVE ONCOLOGY, INC.
    • LABCORP
    • IQVIA INC.
    • TENCENT HOLDINGS LIMITED
    • CELSIUS THERAPEUTICS
    • CYTOREASON
    • OWKIN, INC.
    • CLOUD PHARMACEUTICALS
    • EVAXION BIOTECH
    • STANDIGM
    • BIOAGE LABS
    • ENVISAGENICS
    • ARIA PHARMACEUTICALS, INC.

第16章附錄

簡介目錄
Product Code: HIT 7445

Report Description

Scope of the Report
Years Considered for the Study2021-2028
Base Year2022
Forecast Period2023-2028
Units ConsideredValue (USD) Billion
SegmentsOffering, Therapeutic Area, Process, Use Cases, Technology, End User, Region
Regions coveredNorth America, Europe, Asia Pacific, South America, and Middle East & Africa

The artificial intelligence (AI) in drug discovery market is projected to reach USD 4.9 billion by 2028 from USD 0.9 billion in 2023, at a CAGR of 40.2% during the forecast period. AI expedites the identification and validation of potential drug targets by analyzing intricate biological data. This accelerates the selection of biologically relevant targets for therapeutic interventions. AI techniques such as machine learning enable rapid analysis and decision-making, reducing the time and resources required for drug discovery processes. This efficiency gains a competitive edge in the fast-paced pharmaceutical landscape. Therefore, aforementioned factors will drive the growth of this market. On the other hand, the inadequate availability of skilled labor is key factor restraining the market growth to a certain extent over the forecast period.

"Services segment is estimated to hold the major share in 2022 and also expected to grow at the highest over the forecast period."

Based on offering, the AI in drug discovery market is bifurcated into software and services. The2022 and segment expected to account for the largest market share of the global AI in drug discovery services market in 2022 and expected to grow fastest CAGR during the forecast period. Access to AI technology and expertise through services reduces the barriers for pharmaceutical companies to adopt AI in drug discovery. This is particularly beneficial for smaller companies without extensive in-house AI capabilities, enabling them to harness the power of AI without significant upfront investments.

"Machine learning technology segment accounted for the largest share of the global AI in drug discovery market."

Based on technology, the AI in drug discovery market is segmented into machine learning, natural language processing (NLP), context aware processing, and other technologies. The machine learning segment accounted for the largest share of the global market in 2022 and expected to grow at the highest CAGR during the forecast period. Machine learning enables the creation of predictive models that anticipate the behavior of potential drug candidates within the human body. This aids in identifying compounds with the highest likelihood of success, reducing the costs and time associated with unsuccessful candidates. Machine learning contributes to the development of personalized treatment strategies by analyzing patient data to predict individual responses to drugs. This facilitates tailoring treatments based on genetic, molecular, and clinical information, leading to more effective outcomes, which helps accelerate the drug discovery process are some of the factors supporting the market growth of this segment.

"Small Molecule Design and Optimization segment expected to hold the largest share of use case segment of the market in 2022."

Based on use cases, the AI in drug discovery market is divided into small molecule design and optimization, understanding disease, safety and toxicity, vaccine design and optimization, antibody and other biologics design and optimization. In 2022, the small molecule design and optimization segment accounted for the largest share of the AI in drug discovery market. AI is employed in small molecule design and optimization for two main purposes. Firstly, it aids in identifying hit-like or lead-like compounds by screening existing chemical libraries or through generative de novo design. Secondly, AI optimizes the identified hits, ensuring favorable properties like binding affinity, toxicity, and synthesis, ultimately leading to the development of more effective and safer drug candidates. These factors contribute to the development and refinement of AI algorithms tailored for drug discovery use cases.

"North America to dominate the AI in drug discovery market in 2022"

The global AI in the drug discovery market is segmented into four major regions, namely, North America, Europe, APAC, and the Rest of the World. In 2022, North America accounted for the largest and the fastest-growing regional market for AI in drug discovery. North America hosts numerous pharmaceutical giants and biotechnology innovators that are actively exploring AI's capabilities in drug discovery. These industry leaders are investing significantly in AI-driven research and development, driving market growth. North America's well-established regulatory framework for pharmaceuticals and healthcare facilitates the integration of AI technologies while ensuring compliance with industry standards and guidelines. The above-mentioned factors will drive the market of AI in drug discovery in North America.

Breakdown of supply-side, demand side, primary interviews, by company type, designation, and region:

By Company Type:

  • By Supply Side: Tier 1 (31%), Tier 2 (28%), and Tier 3 (41%)
  • By Demand Side: Purchase Managers (45%), Head of Artificial Intelligence, Machine Learning, Drug Discovery, and Computational Molecular Design (30%) and Research Scientists (25%).
  • By Designation: C-level (31%), Director-level (25%), and Others (44%)
  • By Region: North America (45%), Europe (20%), Asia Pacific (28%), South America (4%) and Middle East & Africa (3%).

The prominent players in this market are NVIDIA Corporation (US), Exscientia (UK), BenevolentAI (UK), Recursion (US), Insilico Medicine (US), Schrodinger, Inc. (US), Microsoft Corporation (US), Google (US), Atomwise Inc. (US), Illumina, Inc. (US), NuMedii, Inc. (US), XtalPi Inc. (US), Iktos (France), Tempus Labs (US), Deep Genomics, Inc. (Canada), Verge Genomics (US), BenchSci (Canada), Insitro (US), Valo Health (US), BPGbio, Inc. (US), IQVIA Inc (US), Labcorp (US), Tencent Holdings Limited (China), Predictive Oncology, Inc. (US), Celsius Therapeutics (US), CytoReason (Israel), Owkin, Inc. (US), Cloud Pharmaceuticals (US), Evaxion Biotech (Denmark), Standigm (South Korea), BIOAGE (US), Envisagenics (US), and Aria Pharmaceuticals, Inc. (US). Players adopted organic as well as inorganic growth strategies such as product launches and enhancements, and investments, partnerships, collaborations, joint ventures, funding, acquisition, expansions, agreements, sales contracts, and alliances to increase their offerings, cater to the unmet needs of customers, increase their profitability, and expand their presence in the global market.

Research Coverage

  • The report studies the AI in drug discovery market based on offering, technology, therapeutic area, use case, process, end user, and region.
  • The report analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth.
  • The report evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders.
  • The report studies micro-markets with respect to their growth trends, prospects, and contributions to the total AI in drug discovery market.
  • The report forecasts the revenue of market segments with respect to five major regions.

Reasons to Buy the Report

The report can help established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one or a combination of the below-mentioned five strategies.

This report provides insights into the following pointers:

  • Analysis of key drivers (growing number of cross-industry collaborations and partnerships, growing need to control drug discovery & development costs and reduce time involved in drug development, patent expiry of several drugs), restraints (shortage of AI workforce and ambiguous regulatory guidelines for medical software), opportunities (growing biotechnology industry, emerging markets, focus on developing human-aware AI systems, growth in the drugs and biologics market despite the COVID-19 pandemic), and challenges (limited availability of data sets) influencing the growth of AI in drug discovery market.
  • Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and product launches in the AI in drug discovery market.
  • Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various types of AI in drug discovery solutions across regions.
  • Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in the AI in drug discovery market.
  • Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the AI in drug discovery market.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS AND EXCLUSIONS
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKET SEGMENTATION
    • FIGURE 1 AI IN DRUG DISCOVERY MARKET: MARKET SEGMENTATION
    • 1.3.2 REGIONAL SCOPE
    • 1.3.3 YEARS CONSIDERED
    • 1.3.4 CURRENCY CONSIDERED
    • TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD
  • 1.4 STAKEHOLDERS
  • 1.5 SUMMARY OF CHANGES
    • 1.5.1 RECESSION IMPACT

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • FIGURE 2 RESEARCH DESIGN
  • 2.2 SECONDARY SOURCES
    • 2.2.1 KEY DATA FROM SECONDARY SOURCES
  • 2.3 PRIMARY DATA
    • 2.3.1 PRIMARY SOURCES
      • 2.3.1.1 Key data from primary sources
      • 2.3.1.2 Key industry insights
    • 2.3.2 BREAKDOWN OF PRIMARY INTERVIEWS
    • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY DEMAND SIDE, SUPPLY SIDE, DESIGNATION, AND REGION
  • 2.4 MARKET SIZE ESTIMATION
    • FIGURE 4 SUPPLY-SIDE MARKET ESTIMATION: REVENUE SHARE ANALYSIS
    • FIGURE 5 BOTTOM-UP APPROACH: END-USER SPENDING ON AI IN DRUG DISCOVERY
    • TABLE 2 FACTOR ANALYSIS
    • FIGURE 6 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2022-2027)
    • FIGURE 7 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
    • FIGURE 8 TOP-DOWN APPROACH
  • 2.5 MARKET BREAKDOWN AND DATA TRIANGULATION
    • FIGURE 9 DATA TRIANGULATION METHODOLOGY
  • 2.6 ASSUMPTIONS
    • 2.6.1 MARKET SIZING ASSUMPTIONS
    • 2.6.2 OVERALL STUDY ASSUMPTIONS
  • 2.7 LIMITATIONS
  • 2.8 RISK ASSESSMENT
    • TABLE 3 RISK ASSESSMENT: AI IN DRUG DISCOVERY MARKET
  • 2.9 RECESSION IMPACT ANALYSIS
    • TABLE 4 GLOBAL INFLATION RATE PROJECTIONS, 2021-2027 (% GROWTH)
    • TABLE 5 US HEALTH EXPENDITURE, 2019-2022 (USD MILLION)
    • TABLE 6 US HEALTH EXPENDITURE, 2023-2027 (USD MILLION)

3 EXECUTIVE SUMMARY

    • FIGURE 10 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2023 VS. 2028 (USD MILLION)
    • FIGURE 11 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION)
    • FIGURE 12 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2023 VS. 2028 (USD MILLION)
    • FIGURE 13 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2023 VS. 2028 (USD MILLION)
    • FIGURE 14 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2023 VS. 2028 (USD MILLION)
    • FIGURE 15 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
    • FIGURE 16 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: GEOGRAPHICAL SNAPSHOT

4 PREMIUM INSIGHTS

  • 4.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN AI IN DRUG DISCOVERY MARKET
    • FIGURE 17 GROWING NUMBER OF CROSS-INDUSTRY COLLABORATIONS & PARTNERSHIPS TO DRIVE MARKET
  • 4.2 AI IN DRUG DISCOVERY MARKET: REGIONAL LANDSCAPE
    • FIGURE 18 NORTH AMERICA TO DOMINATE AI IN DRUG DISCOVERY MARKET DURING FORECAST PERIOD
  • 4.3 AI IN DRUG DISCOVERY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
    • FIGURE 19 US TO REGISTER HIGHEST REVENUE GROWTH FROM 2023 TO 2028
  • 4.4 NORTH AMERICAN AI IN DRUG DISCOVERY MARKET, BY END USER & COUNTRY, 2022
    • FIGURE 20 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND US HELD LARGEST SHARE IN NORTH AMERICA, 2022
  • 4.5 AI IN DRUG DISCOVERY MARKET, BY OFFERING
    • FIGURE 21 SERVICES TO HOLD MAJORITY MARKET SHARE IN 2028
  • 4.6 AI IN DRUG DISCOVERY MARKET, BY TECHNOLOGY
    • FIGURE 22 MACHINE LEARNING TO RETAIN MARKET LEADERSHIP TILL 2028
  • 4.7 AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA
    • FIGURE 23 ONCOLOGY TO DOMINATE MARKET IN 2028
  • 4.8 AI IN DRUG DISCOVERY MARKET, BY PROCESS
    • FIGURE 24 HIT-TO LEAD IDENTIFICATION/LEAD GENERATION TO DOMINATE MARKET IN 2028
  • 4.9 AI IN DRUG DISCOVERY MARKET, BY USE CASE
    • FIGURE 25 SMALL MOLECULE DESIGN & OPTIMIZATION TO REGISTER HIGHEST GROWTH OVER FORECAST PERIOD
  • 4.10 AI IN DRUG DISCOVERY MARKET, BY END USER
    • FIGURE 26 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO ACCOUNT FOR LARGEST MARKET SHARE IN 2028

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 27 AI IN DRUG DISCOVERY: MARKET DYNAMICS
    • TABLE 7 AI IN DRUG DISCOVERY MARKET: IMPACT ANALYSIS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Growing cross-industry collaborations and partnerships
    • TABLE 8 INDICATIVE LIST OF COLLABORATIONS AND PARTNERSHIPS (2021-2023)
      • 5.2.1.2 Growing need to reduce time and cost of drug discovery and development
      • 5.2.1.3 Patent expiry of several drugs
    • TABLE 9 INDICATIVE LIST OF DRUGS LOSING PATENTS IN 2023
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Shortage of AI workforce and ambiguous regulatory guidelines for medical software
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Growing biotechnology industry
      • 5.2.3.2 Emerging markets
      • 5.2.3.3 Focus on developing human-aware AI systems
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Limited availability of data sets
      • 5.2.4.2 Lack of required tools and usability

6 INDUSTRY INSIGHTS

  • 6.1 OVERVIEW OF KEY INDUSTRY TRENDS
    • 6.1.1 EVOLUTION OF AI IN DRUG DISCOVERY
    • FIGURE 28 EVOLUTION OF AI IN DRUG DISCOVERY MARKET
    • 6.1.2 COMPUTER-AIDED DRUG DESIGN AND AI
    • FIGURE 29 STRUCTURE-BASED DRUG DESIGNING: AI IN DRUG DISCOVERY MARKET
  • 6.2 SUPPLY CHAIN ANALYSIS
    • FIGURE 30 AI IN DRUG DISCOVERY MARKET: SUPPLY CHAIN ANALYSIS (2022)
  • 6.3 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 10 AI IN DRUG DISCOVERY MARKET: PORTER'S FIVE FORCES ANALYSIS
    • 6.3.1 INTENSITY OF COMPETITIVE RIVALRY
    • 6.3.2 BARGAINING POWER OF BUYERS
    • 6.3.3 BARGAINING POWER OF SUPPLIERS
    • 6.3.4 THREAT OF SUBSTITUTES
    • 6.3.5 THREAT OF NEW ENTRANTS
  • 6.4 ECOSYSTEM/MARKET MAP
    • FIGURE 31 AI IN DRUG DISCOVERY MARKET ECOSYSTEM
  • 6.5 TECHNOLOGY ANALYSIS
    • FIGURE 32 AI IN DRUG DISCOVERY MARKET: CLASSIFICATION
    • 6.5.1 DRY LAB SERVICES
    • 6.5.2 WET LAB SERVICES
      • 6.5.2.1 Chemistry services
      • 6.5.2.2 BIOLOGICAL SERVICES
        • 6.5.2.2.1 Single-cell analysis
  • 6.6 PRICING ANALYSIS
    • 6.6.1 AVERAGE SELLING PRICE TRENDS, BY REGION
    • 6.6.2 INDICATIVE PRICING ANALYSIS, BY PROCESS
    • TABLE 11 AI IN DRUG DISCOVERY MARKET: INDICATIVE PRICING, BY PROCESS
  • 6.7 BUSINESS MODELS
    • FIGURE 33 AI IN LIFE SCIENCES: BUSINESS MODELS
    • FIGURE 34 BENEFITS OF HYBRID BUSINESS MODELS
    • FIGURE 35 SPECIALIZATION OF AI COMPANIES OVER TIME
  • 6.8 CASE STUDY ANALYSIS
    • 6.8.1 CASE STUDY 1: BRISTOL MYERS SQUIBB AND EXSCIENTIA
    • 6.8.2 CASE STUDY 2: APEIRON LLC AND EXSCIENTIA
  • 6.9 REGULATORY ANALYSIS
    • 6.9.1 AI IN DRUG DISCOVERY MARKET: REGULATORY LANDSCAPE, BY REGION
    • 6.9.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 12 LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 6.10 PATENT ANALYSIS
    • FIGURE 36 TOP PATENT OWNERS AND APPLICANTS FOR AI IN DRUG DISCOVERY SOLUTIONS (JANUARY 2011-OCTOBER 2023)
    • FIGURE 37 AI IN DRUG DISCOVERY MARKET: PATENT ANALYSIS (JANUARY 2011-OCTOBER 2023)
    • FIGURE 38 TOP APPLICANT COUNTRIES/REGIONS FOR AI IN DRUG DISCOVERY PATENTS (JANUARY 2012-JULY 2023)
    • TABLE 13 LIST OF PATENTS/PATENT APPLICATIONS IN AI IN DRUG DISCOVERY MARKET, 2021-2023
  • 6.11 KEY CONFERENCES & EVENTS (Q1 2023-Q2 2024)
  • 6.12 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
    • FIGURE 39 REVENUE SHIFT IN AI IN DRUG DISCOVERY MARKET
  • 6.13 KEY STAKEHOLDERS & BUYING CRITERIA
    • 6.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • FIGURE 40 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF AI IN DRUG DISCOVERY MARKET
    • 6.13.2 BUYING CRITERIA FOR AI IN DRUG DISCOVERY MARKET
    • FIGURE 41 KEY BUYING CRITERIA FOR END USERS
  • 6.14 AI-DERIVED CLINICAL ASSETS
    • TABLE 14 KEY AI-DERIVED CLINICAL ASSETS, BY COMPANY
  • 6.15 UNMET NEEDS
    • 6.15.1 UNMET NEEDS IN AI IN DRUG DISCOVERY
    • 6.15.2 SINGLE-CELL ANALYSIS LANDSCAPE: KEY CHALLENGES AND PAIN POINTS IN DRUG DISCOVERY
    • 6.15.3 KEY UNMET NEEDS AND PAIN POINTS FOR AI APPLICATIONS IN SINGLE-CELL ANALYSIS FOR DRUG DISCOVERY

7 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING

  • 7.1 INTRODUCTION
    • TABLE 15 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021-2028 (USD MILLION)
  • 7.2 SERVICES
    • 7.2.1 SERVICES SEGMENT TO WITNESS HIGHEST GROWTH
    • TABLE 16 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SERVICES, BY COUNTRY, 2021-2028 (USD MILLION)
  • 7.3 SOFTWARE
    • 7.3.1 BENEFITS OF SOFTWARE IN DRUG DISCOVERY AND STRONG DEMAND AMONG END USERS TO DRIVE GROWTH
    • TABLE 17 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SOFTWARE, BY COUNTRY, 2021-2028 (USD MILLION)

8 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY

  • 8.1 INTRODUCTION
    • TABLE 18 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • 8.2 MACHINE LEARNING
    • TABLE 19 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 20 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY COUNTRY, 2021-2028 (USD MILLION)
    • 8.2.1 DEEP LEARNING
      • 8.2.1.1 Deep learning to see growing adoption in drug discovery
    • TABLE 21 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DEEP LEARNING, BY COUNTRY, 2021-2028 (USD MILLION)
    • 8.2.2 SUPERVISED LEARNING
      • 8.2.2.1 Applications in drug repositioning to drive market
    • TABLE 22 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SUPERVISED LEARNING, BY COUNTRY, 2021-2028 (USD MILLION)
    • 8.2.3 REINFORCEMENT LEARNING
      • 8.2.3.1 Potential for machines and software to automatically determine behavior to support adoption
    • TABLE 23 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR REINFORCEMENT LEARNING, BY COUNTRY, 2021-2028 (USD MILLION)
    • 8.2.4 UNSUPERVISED LEARNING
      • 8.2.4.1 Unpredictability to affect end-user adoption
    • TABLE 24 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR UNSUPERVISED LEARNING, BY COUNTRY, 2021-2028 (USD MILLION)
    • 8.2.5 OTHER MACHINE LEARNING TECHNOLOGIES
    • TABLE 25 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER MACHINE LEARNING TECHNOLOGIES, BY COUNTRY, 2021-2028 (USD MILLION)
  • 8.3 NATURAL LANGUAGE PROCESSING
    • 8.3.1 POTENTIAL APPLICATIONS IN DATA IDENTIFICATION TO SUPPORT GROWTH
    • TABLE 26 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR NATURAL LANGUAGE PROCESSING, BY COUNTRY, 2021-2028 (USD MILLION)
  • 8.4 CONTEXT-AWARE PROCESSING & CONTEXT-AWARE COMPUTING
    • 8.4.1 RISING PROCESSING POWER, IMPROVED CONNECTIVITY TO BOOST USAGE
    • TABLE 27 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CONTEXT-AWARE PROCESSING & CONTEXT-AWARE COMPUTING, BY COUNTRY, 2021-2028 (USD MILLION)
  • 8.5 OTHER TECHNOLOGIES
    • TABLE 28 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2021-2028 (USD MILLION)

9 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA

  • 9.1 INTRODUCTION
    • TABLE 29 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
  • 9.2 ONCOLOGY
    • 9.2.1 HIGH PREVALENCE OF CANCER AND SHORTAGE OF EFFECTIVE CANCER DRUGS TO DRIVE SEGMENT GROWTH
    • TABLE 30 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR ONCOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
  • 9.3 INFECTIOUS DISEASES
    • 9.3.1 RISING EPIDEMIC OUTBREAKS TO BOOST DRUG DISCOVERY ACTIVITY
    • TABLE 31 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
  • 9.4 NEUROLOGY
    • 9.4.1 NEED TO BOOST DISCOVERY AND DEVELOPMENT TO DRIVE MARKET
    • TABLE 32 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR NEUROLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
  • 9.5 CARDIOVASCULAR DISEASES
    • 9.5.1 RISING DEMAND FOR CVD DRUGS TO DRIVE SEGMENT
    • TABLE 33 INDICATIVE LIST OF DEVELOPMENTS IN CARDIOVASCULAR DRUG DEVELOPMENT
    • TABLE 34 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
  • 9.6 IMMUNOLOGY
    • 9.6.1 GROWING DRUG PIPELINE FOR IMMUNOLOGICAL DISORDERS TO FAVOR MARKET GROWTH
    • TABLE 35 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
  • 9.7 METABOLIC DISEASES
    • 9.7.1 ROLE OF AI IN UNCOVERING SMALL-MOLECULE THERAPIES TO DRIVE ADOPTION
    • TABLE 36 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
  • 9.8 OTHER THERAPEUTIC AREAS
    • TABLE 37 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021-2028 (USD MILLION)

10 AI IN DRUG DISCOVERY MARKET, BY PROCESS

  • 10.1 INTRODUCTION
    • FIGURE 42 HIT-TO-LEAD IDENTIFICATION/LEAD GENERATION SEGMENT HELD LARGEST MARKET SHARE IN 2022
    • TABLE 38 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021-2028 (USD MILLION)
  • 10.2 TARGET IDENTIFICATION & SELECTION
    • 10.2.1 DEVELOPMENT OF NEW TECHNOLOGIES TO SUPPORT MARKET GROWTH
    • TABLE 39 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR TARGET IDENTIFICATION & SELECTION, BY COUNTRY, 2021-2028 (USD MILLION)
  • 10.3 TARGET VALIDATION
    • 10.3.1 RISING EMPHASIS ON TARGET VALIDATION TO AVOID LATE-STAGE FAILURE
    • TABLE 40 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR TARGET VALIDATION, BY COUNTRY, 2021-2028 (USD MILLION)
  • 10.4 HIT IDENTIFICATION & PRIORITIZATION
    • 10.4.1 NEED FOR LARGE-SCALE DATA ANALYSIS TO DRIVE ADOPTION
    • TABLE 41 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR HIT IDENTIFICATION & PRIORITIZATION, BY COUNTRY, 2021-2028 (USD MILLION)
  • 10.5 HIT-TO-LEAD IDENTIFICATION/LEAD GENERATION
    • 10.5.1 HIT-TO-LEAD IDENTIFICATION TO HOLD LARGEST MARKET SHARE
    • TABLE 42 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR HIT-TO-LEAD IDENTIFICATION/LEAD GENERATION, BY COUNTRY, 2021-2028 (USD MILLION)
  • 10.6 LEAD OPTIMIZATION
    • 10.6.1 NEED FOR TRANSPARENT PRESENTATION AND ANALYSIS TO BOOST FOCUS ON LEAD OPTIMIZATION
    • TABLE 43 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2021-2028 (USD MILLION)
  • 10.7 CANDIDATE SELECTION & VALIDATION
    • 10.7.1 POSSIBILITY OF DRUG FAILURE DURING DEVELOPMENT TO DRIVE ADOPTION OF CANDIDATE VALIDATION SERVICES
    • TABLE 44 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CANDIDATE SELECTION & VALIDATION, BY COUNTRY, 2021-2028 (USD MILLION)

11 AI IN DRUG DISCOVERY MARKET, BY USE CASE

  • 11.1 INTRODUCTION
    • FIGURE 43 SMALL-MOLECULE DESIGN & OPTIMIZATION SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022
    • TABLE 45 AI IN DRUG DISCOVERY MARKET, BY USE CASE, 2021-2028 (USD MILLION)
  • 11.2 SMALL-MOLECULE DESIGN & OPTIMIZATION
    • 11.2.1 AVAILABILITY OF WELL-VALIDATED AI TOOLS TO BOOST MARKET GROWTH
    • TABLE 46 AI IN DRUG DISCOVERY MARKET FOR SMALL-MOLECULE DESIGN & OPTIMIZATION, BY COUNTRY, 2021-2028 (USD MILLION)
  • 11.3 UNDERSTANDING DISEASE
    • 11.3.1 RISING DATA MINING TO LINK TARGETS TO DISEASES AND DRUG REPURPOSING TO DRIVE MARKET
    • TABLE 47 AI IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASE, BY COUNTRY, 2021-2028 (USD MILLION)
  • 11.4 SAFETY & TOXICITY
    • 11.4.1 TOXICOLOGY AND OFF-TARGET EFFECT PREDICTION, PK/PD SIMULATION, AND QSP MODELING TO PROPEL MARKET GROWTH
    • TABLE 48 AI IN DRUG DISCOVERY MARKET FOR SAFETY & TOXICITY, BY COUNTRY, 2021-2028 (USD MILLION)
  • 11.5 VACCINE DESIGN & OPTIMIZATION
    • 11.5.1 GROWING ADOPTION OF AI FOR EPITOPE SELECTION, PREDICTION, AND BINDING TO AUGMENT MARKET GROWTH
    • TABLE 49 AI IN DRUG DISCOVERY MARKET FOR VACCINE DESIGN & OPTIMIZATION, BY COUNTRY, 2021-2028 (USD MILLION)
  • 11.6 ANTIBODY & OTHER BIOLOGIC DESIGN & OPTIMIZATION
    • 11.6.1 GROWING ADOPTION OF AI FOR ANTIBODY PROPERTY PREDICTION TO DRIVE MARKET
    • TABLE 50 AI IN DRUG DISCOVERY MARKET FOR ANTIBODY & OTHER BIOLOGIC DESIGN & OPTIMIZATION, BY COUNTRY, 2021-2028 (USD MILLION)

12 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER

  • 12.1 INTRODUCTION
    • TABLE 51 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 12.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    • 12.2.1 RISING DEMAND FOR SOLUTIONS TO CUT TIME AND COSTS OF DRUG DEVELOPMENT TO DRIVE MARKET
    • TABLE 52 INDICATIVE LIST OF DEVELOPMENTS RELATED TO AI IN PHARMACEUTICAL & BIOTECHNOLOGY INDUSTRY
    • TABLE 53 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION)
  • 12.3 CONTRACT RESEARCH ORGANIZATIONS
    • 12.3.1 GROWING TREND OF OUTSOURCING TO PROVIDE SIGNIFICANT OPPORTUNITIES FOR CONTRACT RESEARCH ORGANIZATIONS
    • TABLE 54 INDICATIVE LIST OF COLLABORATIONS WITH CROS
    • TABLE 55 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
  • 12.4 RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES
    • 12.4.1 SEGMENT TO REGISTER HIGHEST CAGR OVER FORECAST PERIOD
    • TABLE 56 INDICATIVE LIST OF RESEARCH COLLABORATIONS
    • TABLE 57 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES, BY COUNTRY, 2021-2028 (USD MILLION)

13 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY REGION

  • 13.1 INTRODUCTION
    • TABLE 58 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY REGION, 2021-2028 (USD MILLION)
  • 13.2 NORTH AMERICA
    • 13.2.1 NORTH AMERICA: RECESSION IMPACT
    • FIGURE 44 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SNAPSHOT
    • TABLE 59 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 60 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021-2028 (USD MILLION)
    • TABLE 61 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 62 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 63 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • TABLE 64 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 65 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021-2028 (USD MILLION)
    • TABLE 66 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 13.2.2 US
      • 13.2.2.1 Strong economy and trend of early adoption of technologies to drive market
    • FIGURE 45 DISTRIBUTION OF R&D COMPANIES, BY COUNTRY/REGION (2021 VS. 2022)
    • TABLE 67 US: INDICATIVE LIST OF STRATEGIC DEVELOPMENTS
    • TABLE 68 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021-2028 (USD MILLION)
    • TABLE 69 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 70 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 71 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA 2021-2028 (USD MILLION)
    • TABLE 72 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS 2021-2028 (USD MILLION)
    • TABLE 73 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021-2028 (USD MILLION)
    • TABLE 74 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 13.2.3 CANADA
      • 13.2.3.1 Growing research on AI technologies and emergence of new AI-based start-ups to support market growth
    • TABLE 75 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021-2028 (USD MILLION)
    • TABLE 76 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 77 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 78 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • TABLE 79 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 80 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021-2028 (USD MILLION)
    • TABLE 81 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 13.2.4 MEXICO
      • 13.2.4.1 Government initiatives to support market growth
    • TABLE 82 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021-2028 (USD MILLION)
    • TABLE 83 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 84 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 85 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • TABLE 86 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 87 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021-2028 (USD MILLION)
    • TABLE 88 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 13.3 EUROPE
    • 13.3.1 EUROPE: RECESSION IMPACT
    • TABLE 89 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 90 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021-2028 (USD MILLION)
    • TABLE 91 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 92 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 93 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • TABLE 94 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 95 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021-2028 (USD MILLION)
    • TABLE 96 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 13.3.2 UK
      • 13.3.2.1 UK to hold largest share in Europe
    • TABLE 97 UK: INDICATIVE LIST OF STRATEGIC DEVELOPMENTS
    • TABLE 98 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021-2028 (USD MILLION)
    • TABLE 99 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 100 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 101 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • TABLE 102 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 103 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021-2028 (USD MILLION)
    • TABLE 104 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 13.3.3 GERMANY
      • 13.3.3.1 Government support and favorable training programs to propel market growth
    • TABLE 105 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021-2028 (USD MILLION)
    • TABLE 106 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 107 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 108 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • TABLE 109 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 110 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021-2028 (USD MILLION)
    • TABLE 111 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 13.3.4 FRANCE
      • 13.3.4.1 Strong government support and favorable strategies & initiatives to drive market
    • TABLE 112 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021-2028 (USD MILLION)
    • TABLE 113 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 114 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 115 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • TABLE 116 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 117 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021-2028 (USD MILLION)
    • TABLE 118 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 13.3.5 ITALY
      • 13.3.5.1 Strong pharmaceutical industry to support market growth
    • TABLE 119 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021-2028 (USD MILLION)
    • TABLE 120 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 121 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 122 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • TABLE 123 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 124 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021-2028 (USD MILLION)
    • TABLE 125 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 13.3.6 REST OF EUROPE
    • TABLE 126 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021-2028 (USD MILLION)
    • TABLE 127 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 128 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 129 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • TABLE 130 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 131 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021-2028 (USD MILLION)
    • TABLE 132 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 13.4 ASIA PACIFIC
    • 13.4.1 ASIA PACIFIC: RECESSION IMPACT
    • TABLE 133 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 134 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021-2028 (USD MILLION)
    • TABLE 135 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 136 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 137 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • TABLE 138 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 139 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021-2028 (USD MILLION)
    • TABLE 140 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 13.4.2 JAPAN
      • 13.4.2.1 Japan to dominate APAC market
    • TABLE 141 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021-2028 (USD MILLION)
    • TABLE 142 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 143 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 144 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • TABLE 145 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 146 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021-2028 (USD MILLION)
    • TABLE 147 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 13.4.3 CHINA
      • 13.4.3.1 Growing CMO market and cross-industry collaborations to drive market
    • TABLE 148 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021-2028 (USD MILLION)
    • TABLE 149 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 150 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 151 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • TABLE 152 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 153 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021-2028 (USD MILLION)
    • TABLE 154 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 13.4.4 INDIA
      • 13.4.4.1 Steady adoption of AI technologies to support market growth
    • TABLE 155 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021-2028 (USD MILLION)
    • TABLE 156 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 157 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 158 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • TABLE 159 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 160 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021-2028 (USD MILLION)
    • TABLE 161 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 13.4.5 REST OF ASIA PACIFIC
    • TABLE 162 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021-2028 (USD MILLION)
    • TABLE 163 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 164 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 165 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • TABLE 166 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 167 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021-2028 (USD MILLION)
    • TABLE 168 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 13.5 SOUTH AMERICA
    • 13.5.1 SHORTAGE OF SKILLED LABOR AND GROWING REQUIREMENTS TO DRIVE AI ADOPTION
    • 13.5.2 SOUTH AMERICA: RECESSION IMPACT
    • TABLE 169 SOUTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021-2028 (USD MILLION)
    • TABLE 170 SOUTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 171 SOUTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 172 SOUTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • TABLE 173 SOUTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 174 SOUTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021-2028 (USD MILLION)
    • TABLE 175 SOUTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 13.6 MIDDLE EAST & AFRICA
    • 13.6.1 LIMITED COMPANY PRESENCE AND LARGE SCOPE FOR GROWTH TO FAVOR AI MARKET
    • 13.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT
    • TABLE 176 MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021-2028 (USD MILLION)
    • TABLE 177 MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 178 MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 179 MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • TABLE 180 MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 181 MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021-2028 (USD MILLION)
    • TABLE 182 MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021-2028 (USD MILLION)

14 COMPETITIVE LANDSCAPE

  • 14.1 KEY PLAYER STRATEGIES/RIGHT TO WIN
    • TABLE 183 OVERVIEW OF STRATEGIES ADOPTED BY KEY AI IN DRUG DISCOVERY PLAYERS, FEBRUARY 2021- MAY 2022
  • 14.2 REVENUE ANALYSIS
    • FIGURE 46 REVENUE ANALYSIS OF TOP MARKET PLAYERS, 2022
  • 14.3 MARKET SHARE ANALYSIS
    • FIGURE 47 AI IN DRUG DISCOVERY MARKET: MARKET SHARE ANALYSIS, 2022
    • TABLE 184 AI IN DRUG DISCOVERY MARKET: DEGREE OF COMPETITION
  • 14.4 COMPANY EVALUATION MATRIX
    • 14.4.1 STARS
    • 14.4.2 EMERGING LEADERS
    • 14.4.3 PERVASIVE PLAYERS
    • 14.4.4 PARTICIPANTS
    • FIGURE 48 AI IN DRUG DISCOVERY MARKET: COMPANY EVALUATION MATRIX, 2022
    • 14.4.5 COMPANY FOOTPRINT
    • TABLE 185 USE CASE FOOTPRINT (24 COMPANIES)
    • TABLE 186 PROCESS FOOTPRINT (24 COMPANIES)
    • TABLE 187 REGION FOOTPRINT (24 COMPANIES)
    • TABLE 188 COMPANY FOOTPRINT (24 COMPANIES)
  • 14.5 START-UP/SME EVALUATION MATRIX
    • 14.5.1 PROGRESSIVE COMPANIES
    • 14.5.2 RESPONSIVE COMPANIES
    • 14.5.3 DYNAMIC COMPANIES
    • 14.5.4 STARTING BLOCKS
    • FIGURE 49 AI IN DRUG DISCOVERY MARKET: START-UP/SME EVALUATION MATRIX, 2022
    • 14.5.5 AI IN DRUG DISCOVERY MARKET: COMPETITIVE BENCHMARKING
    • TABLE 189 AI IN DRUG DISCOVERY MARKET: DETAILED LIST OF KEY SMES/START-UPS
    • TABLE 190 USE CASE FOOTPRINT (START-UPS/SMES)
    • TABLE 191 PROCESS FOOTPRINT (START-UPS/SMES)
    • TABLE 192 REGION FOOTPRINT (START-UPS/SMES)
    • TABLE 193 COMPANY FOOTPRINT (START-UPS/SMES)
  • 14.6 COMPETITIVE SCENARIOS AND TRENDS
    • 14.6.1 PRODUCT LAUNCHES & ENHANCEMENTS
    • TABLE 194 AI IN DRUG DISCOVERY MARKET: PRODUCT LAUNCHES & ENHANCEMENTS, 2021-2023
    • 14.6.2 DEALS
    • TABLE 195 AI IN DRUG DISCOVERY MARKET: DEALS, 2021-2023
    • 14.6.3 OTHER DEVELOPMENTS
    • TABLE 196 AI IN DRUG DISCOVERY MARKET: OTHER DEVELOPMENTS, 2021-2023

15 COMPANY PROFILES

  • 15.1 KEY PLAYERS
  • (Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))**
    • 15.1.1 NVIDIA CORPORATION
    • TABLE 197 NVIDIA CORPORATION: COMPANY OVERVIEW
    • FIGURE 50 NVIDIA CORPORATION: COMPANY SNAPSHOT, 2022
    • TABLE 198 NVIDIA CORPORATION: PRODUCTS/SOLUTIONS/SERVICES OFFERED
    • TABLE 199 NVIDIA CORPORATION: PRODUCT/SERVICE LAUNCHES
    • TABLE 200 NVIDIA CORPORATION: DEALS
    • 15.1.2 EXSCIENTIA
    • TABLE 201 EXSCIENTIA: COMPANY OVERVIEW
    • FIGURE 51 EXSCIENTIA: COMPANY SNAPSHOT (2022)
    • TABLE 202 EXSCIENTIA: PRODUCTS/SOLUTIONS/SERVICES OFFERED
    • TABLE 203 EXSCIENTIA: PRODUCT/SERVICE LAUNCHES
    • TABLE 204 EXSCIENTIA: DEALS
    • TABLE 205 EXSCIENTIA: OTHER DEVELOPMENTS
    • 15.1.3 GOOGLE
    • TABLE 206 GOOGLE: COMPANY OVERVIEW
    • FIGURE 52 GOOGLE: COMPANY SNAPSHOT (2022)
    • TABLE 207 GOOGLE: PRODUCTS/SOLUTIONS/SERVICES OFFERED
    • TABLE 208 GOOGLE: PRODUCT/SERVICE LAUNCHES
    • TABLE 209 GOOGLE: DEALS
    • TABLE 210 GOOGLE: OTHER DEVELOPMENTS
    • 15.1.4 BENEVOLENTAI
    • TABLE 211 BENEVOLENTAI: COMPANY OVERVIEW
    • FIGURE 53 BENEVOLENTAI: COMPANY SNAPSHOT (2022)
    • TABLE 212 BENEVOLENTAI: PRODUCTS/SOLUTIONS/SERVICES OFFERED
    • TABLE 213 BENEVOLENTAI: DEALS
    • 15.1.5 RECURSION
    • TABLE 214 RECURSION: COMPANY OVERVIEW
    • FIGURE 54 RECURSION: COMPANY SNAPSHOT (2022)
    • TABLE 215 RECURSION: PRODUCTS/SOLUTIONS/SERVICES OFFERED
    • TABLE 216 RECURSION: PRODUCT/SERVICE LAUNCHES
    • TABLE 217 RECURSION: DEALS
    • TABLE 218 RECURSION: OTHER DEVELOPMENTS
    • 15.1.6 INSILICO MEDICINE
    • TABLE 219 INSILICO MEDICINE: COMPANY OVERVIEW
    • TABLE 220 INSILICO MEDICINE: PRODUCTS/SOLUTIONS/SERVICES OFFERED
    • TABLE 221 INSILICO MEDICINE: PRODUCT/SERVICE LAUNCHES
    • TABLE 222 INSILICO MEDICINE: DEALS
    • TABLE 223 INSILICO MEDICINE: OTHER DEVELOPMENTS
    • 15.1.7 SCHRODINGER, INC.
    • TABLE 224 SCHRODINGER, INC.: COMPANY OVERVIEW
    • FIGURE 55 SCHRODINGER, INC.: COMPANY SNAPSHOT (2022)
    • TABLE 225 SCHRODINGER, INC.: PRODUCTS/SOLUTIONS/SERVICES OFFERED
    • TABLE 226 SCHRODINGER, INC.: DEALS
    • TABLE 227 SCHRODINGER, INC.: OTHER DEVELOPMENTS
    • 15.1.8 MICROSOFT CORPORATION
    • TABLE 228 MICROSOFT CORPORATION: COMPANY OVERVIEW
    • FIGURE 56 MICROSOFT CORPORATION: COMPANY SNAPSHOT (2023)
    • TABLE 229 MICROSOFT CORPORATION: PRODUCTS/SOLUTIONS/SERVICES OFFERED
    • TABLE 230 MICROSOFT CORPORATION: SERVICE LAUNCHES
    • TABLE 231 MICROSOFT CORPORATION: DEALS
    • 15.1.9 ATOMWISE INC.
    • TABLE 232 ATOMWISE INC.: COMPANY OVERVIEW
    • TABLE 233 ATOMWISE INC.: PRODUCTS/SOLUTIONS/SERVICES OFFERED
    • TABLE 234 ATOMWISE INC.: DEALS
    • 15.1.10 ILLUMINA, INC.
    • TABLE 235 ILLUMINA, INC.: COMPANY OVERVIEW
    • FIGURE 57 ILLUMINA, INC.: COMPANY SNAPSHOT (2022)
    • TABLE 236 ILLUMINA, INC.: PRODUCTS/SOLUTIONS/SERVICES OFFERED
    • TABLE 237 ILLUMINA, INC.: PRODUCT/SERVICE LAUNCHES
    • TABLE 238 ILLUMINA, INC.: DEALS
    • 15.1.11 NUMEDII, INC.
    • TABLE 239 NUMEDII, INC.: COMPANY OVERVIEW
    • TABLE 240 NUMEDII, INC.: PRODUCTS/SOLUTIONS/SERVICES OFFERED
    • 15.1.12 XTALPI INC.
    • TABLE 241 XTALPI INC.: COMPANY OVERVIEW
    • TABLE 242 XTALPI INC.: PRODUCTS/SOLUTIONS/SERVICES OFFERED
    • TABLE 243 XTALPI INC.: DEALS
    • 15.1.13 IKTOS
    • TABLE 244 IKTOS: COMPANY OVERVIEW
    • TABLE 245 IKTOS: PRODUCTS/SOLUTIONS/SERVICES OFFERED
    • TABLE 246 IKTOS: DEALS
    • TABLE 247 IKTOS: OTHER DEVELOPMENTS
    • 15.1.14 TEMPUS LABS
    • TABLE 248 TEMPUS LABS: COMPANY OVERVIEW
    • TABLE 249 TEMPUS LABS: PRODUCTS/SOLUTIONS/SERVICES OFFERED
    • TABLE 250 TEMPUS LABS: PRODUCT/SERVICE LAUNCHES
    • TABLE 251 TEMPUS LABS: DEALS
    • TABLE 252 TEMPUS LABS: OTHER DEVELOPMENTS
    • 15.1.15 DEEP GENOMICS, INC.
    • TABLE 253 DEEP GENOMICS, INC.: COMPANY OVERVIEW
    • TABLE 254 DEEP GENOMICS, INC.: PRODUCTS/SERVICES OFFERED
    • TABLE 255 DEEP GENOMICS, INC.: DEALS
    • TABLE 256 DEEP GENOMICS, INC.: OTHER DEVELOPMENTS
    • 15.1.16 VERGE GENOMICS
    • TABLE 257 VERGE GENOMICS: COMPANY OVERVIEW
    • TABLE 258 VERGE GENOMICS: PRODUCTS/SERVICES OFFERED
    • TABLE 259 VERGE GENOMICS: DEALS
    • 15.1.17 BENCHSCI
    • TABLE 260 BENCHSCI: COMPANY OVERVIEW
    • TABLE 261 BENCHSCI: PRODUCTS/SOLUTIONS/SERVICES OFFERED
    • TABLE 262 BENCHSCI: PRODUCT/SERVICE LAUNCHES
    • TABLE 263 BENCHSCI: OTHER DEVELOPMENTS
    • 15.1.18 INSITRO
    • TABLE 264 INSITRO: COMPANY OVERVIEW
    • TABLE 265 INSITRO: PRODUCTS/SOLUTIONS/SERVICES OFFERED
    • TABLE 266 INSITRO: OTHER DEVELOPMENTS
    • 15.1.19 VALO HEALTH
    • TABLE 267 VALO HEALTH: COMPANY OVERVIEW
    • TABLE 268 VALO HEALTH: PRODUCTS/SOLUTIONS/SERVICES OFFERED
    • TABLE 269 VALO HEALTH: DEALS
    • TABLE 270 VALO HEALTH: OTHER DEVELOPMENTS
    • 15.1.20 BPGBIO, INC.
    • TABLE 271 BPGBIO, INC.: COMPANY OVERVIEW
    • TABLE 272 BPGBIO, INC.: PRODUCTS/SOLUTIONS/SERVICES OFFERED
    • TABLE 273 BPGBIO, INC.: DEALS
  • 15.2 OTHER EMERGING PLAYERS
    • 15.2.1 PREDICTIVE ONCOLOGY, INC.
    • 15.2.2 LABCORP
    • 15.2.3 IQVIA INC.
    • 15.2.4 TENCENT HOLDINGS LIMITED
    • 15.2.5 CELSIUS THERAPEUTICS
    • 15.2.6 CYTOREASON
    • 15.2.7 OWKIN, INC.
    • 15.2.8 CLOUD PHARMACEUTICALS
    • 15.2.9 EVAXION BIOTECH
    • 15.2.10 STANDIGM
    • 15.2.11 BIOAGE LABS
    • 15.2.12 ENVISAGENICS
    • 15.2.13 ARIA PHARMACEUTICALS, INC.
  • *Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

16 APPENDIX

  • 16.1 DISCUSSION GUIDE
  • 16.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 16.3 CUSTOMIZATION OPTIONS
  • 16.4 RELATED REPORTS
  • 16.5 AUTHOR DETAILS